We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Next-Generation Whole-Cell Biosensors May Provide New Approach to Diagnostics

By LabMedica International staff writers
Posted on 08 Jun 2015
Print article
Image: Newly designed bacteria with synthetically rewired genetic circuitry act as bactosensors to detect abnormal glucose levels in urine of diabetes patients (Photo courtesy of Chris Bickel and the journal Science).
Image: Newly designed bacteria with synthetically rewired genetic circuitry act as bactosensors to detect abnormal glucose levels in urine of diabetes patients (Photo courtesy of Chris Bickel and the journal Science).
Image: Illustration of principle for using modified, “programmed” bacteria as “bactodetectors” of molecular markers for medical diagnosis (Photo courtesy of J. Bonnet and INSERM).
Image: Illustration of principle for using modified, “programmed” bacteria as “bactodetectors” of molecular markers for medical diagnosis (Photo courtesy of J. Bonnet and INSERM).
Researchers have developed the first programmable bacterial cells for medical diagnosis with improved computing and amplification capacity that could enable earlier clinical detection of various pathological biomarkers in urine or blood.

Several hurdles have limited the application of whole-cell biosensors as analytical clinical tools, primarily their unreliable operation in complex samples and low signal-to-noise ratio. Teams led by Jerome Bonnet (INSERM, CNRS; Montpellier University; Montpellier, France), Franck Molina (SysDiag, CNRS; Montpellier, France), in association with teams led by Eric Renard (Montpellier Regional University Hospital; Montpellier, France) and Drew Endy (Stanford University; Standford, CA, USA), have transformed bacteria into diagnostic agents by inserting the equivalent of a computer program into their DNA. These “bactosensors” with genetically encoded digital amplifying genetic switches can detect clinically relevant molecular markers. They perform signal digitization and amplification, multiplexed signal processing via Boolean logic gates, and data storage.

In vitro diagnostic (IVD) tests are generally noninvasive and simple, but some are complex, requiring sophisticated technologies often available only in central laboratories. Living cells can detect, process, and respond to many signals. Provided with an appropriate “program” they can accomplish diagnostic tasks. To do this, Jerome Bonnet’s team at had the idea to apply concepts from synthetic biology derived from electronics to construct genetic systems to “program” living cells like a computer.

As a central component of modern electronic instruments (including calculators and smartphones), the transistor acts both as a switch and a signal amplifier. In informatics, several transistors are combined to construct “logic gates” that respond to different signal combinations according to a predetermined logic. For example, a dual input “AND” logic gate will produce a signal only if both of two input signals are present. At Standford University Jerome Bonnet had previously invented a genetic transistor named the “transcriptor.” Inserting transcriptors into bacteria can transform them into calculators, where electrical signals used in electronics are replaced by molecular signals that control gene expression. It is thus possible to reprogram the cells by implanting simple genetic “programs” as sensor modules that enable cells to respond to specific combinations of molecules.

The team now applied this new technology to detect disease “signals” in clinical samples. The transcriptor amplification ability was used to detect biomarkers even at very small amounts, and the test results were successfully stored in the bacterial DNA for several months. Thus, the semi-synthetic cells acquired the ability to perform different functions based on the presence of several markers, opening the way to more accurate diagnostic tests that rely on detection of molecular “signatures” using different biomarkers.

As a proof-of-concept clinical experiment, the transcriptor was connected to a bacterial system that responds to glucose and successfully detected the abnormal levels of glucose in urine of diabetic patients.

“We have standardized our method, and confirmed the robustness of our synthetic bacterial systems in clinical samples. We have also developed a rapid technique for connecting the transcriptor to new detection systems. All this should make it easier to reuse our system,” said first author Alexis Courbet, “Our work is presently focused on the engineering of artificial genetic systems that can be modified on demand to detect different molecular disease markers,” said Jerome Bonnet.

The study, by Courbet A, et al., was published May 27, 2015, in the journal Science Translational Medicine.

Related Links:

INSERM 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.